糖尿病慢性肾脏病患者残余蛋白尿水平与心肾预后:四项队列研究汇总分析
该汇总分析纳入四项接受肾素-血管紧张素系统抑制剂治疗的前瞻性队列研究,比较伴或不伴糖尿病的CKD患者按蛋白尿水平分层后的全因死亡、心血管事件及ESRD风险。结果显示,非蛋白尿性DM-CKD患者心肾风险不增高;而伴中度及以上蛋白尿时,糖尿病本身与死亡和心血管事件风险增高相关,ESRD风险则由蛋白尿水平独立于糖尿病状态所决定。
要点
- 非蛋白尿性DM-CKD患者(尿蛋白<0.15 g/day)的心肾风险与无糖尿病患者相似。
- 伴蛋白尿的DM-CKD患者死亡风险显著增高,HR约1.92–1.99。
- ESRD风险随蛋白尿>0.5 g/day逐级增加,且独立于糖尿病状态。
核心结论
- 非蛋白尿性DM-CKD患者未暴露于更高的心肾风险。
- 存在中度蛋白尿时,糖尿病本身与死亡和心血管事件风险增高相关。
- ESRD风险由异常蛋白尿程度决定,独立于糖尿病状态。
研究设计与样本
- 四项前瞻性队列研究的汇总分析。
- 纳入接受肾素-血管紧张素系统抑制剂治疗的CKD患者,伴糖尿病693例,不伴糖尿病1481例。
- 按蛋白尿水平分层:<0.15、0.15-0.49、0.5-1和>1 g/day。
主要发现
- 随访4.07年期间,发生ESRD 466例、死亡334例、心血管事件401例。
- 尿蛋白<0.15 g/day亚组(N=662)中,糖尿病与非糖尿病患者的ESRD、心血管事件和死亡风险相似。
- DM-CKD患者中,蛋白尿0.15-0.49、0.5-1和>1 g/day的死亡风险HR分别为1.92(95%CI 1.25-2.95)、1.99(1.26-3.15)和1.98(1.28-3.06)。
- 非糖尿病患者中,仅蛋白尿0.5-1 g/day(HR 1.60,95%CI 1.07-2.40)和>1 g/day(HR 1.69,95%CI 1.20-2.55)死亡风险增高。
- 两组中心血管风险趋势与死亡风险相似;ESRD风险在蛋白尿>0.5 g/day各分层中逐级增加,独立于糖尿病状态。
关键数值与推荐
- 蛋白尿分层界值:<0.15、0.15-0.49、0.5-1和>1 g/day。
- DM-CKD组较非糖尿病组年龄更大(69±11 vs 65±15岁),BMI更高(29.6±5.4 vs 27.5±4.8 kg/m2),收缩压更高(143±19 vs 136±18 mmHg),心血管疾病患病率更高(48% vs 29%),eGFR更低(34.5±17.9 vs 36.6±19.0 mL/min/1.73 m2)。
临床怎么用
- 对DM-CKD患者应评估残余蛋白尿水平以进行心肾风险分层。
- 非蛋白尿性DM-CKD患者的心肾风险与无糖尿病患者相似,可能无需强化降糖外的额外干预。
- 伴中度及以上蛋白尿的DM-CKD患者死亡和心血管事件风险更高,需加强心血管风险管理。
- 蛋白尿>0.5 g/day时ESRD风险进行性增加,应强化肾脏保护治疗。
局限性
- 为汇总分析,非随机对照研究,可能存在混杂因素。
- 患者均接受肾素-血管紧张素系统抑制剂治疗,结果外推需谨慎。
- 原文未报告各蛋白尿分层中糖尿病与非糖尿病比较的交互作用P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No study has assessed whether the prognosis of coexisting diabetes mellitus and chronic kidney disease (DM-CKD) is dictated by DM per se or by the extent of proteinuria. METHODS: In this pooled analysis of four prospective studies in CKD patients treated with drugs inhibiting the renin-angiotensin system, we compared the risk of all-cause mortality, fatal and non-fatal cardiovascular (CV) events and end-stage renal disease (ESRD) between patients with (n = 693) and without diabetes (n = 1481) stratified by proteinuria level (<0.15, 0.15-0.49, 0.5-1 and >1 g/day). RESULTS: The group with DM-CKD was older (69 ± 11 versus 65 ± 15 years), had a higher body mass index (29.6 ± 5.4 versus 27.5 ± 4.8 kg/m2) and systolic blood pressure (143 ± 19 versus 136 ± 18 mmHg), prevalent CV disease (48% versus 29%) and lower estimated glomerular filtration rate (34.5 ± 17.9 versus 36.6 ± 19.0 mL/min/1.73 m2). During 4.07 years of follow-up, there were 466 patients with ESRD, 334 deaths and 401 CV events occurred. In the subgroup with urine protein <0.15 g/day (N = 662), the risks of ESRD, CV events and mortality were similar in diabetic and non-diabetic patients. Conversely, in DM-CKD patients, the mortality risk was higher in proteinuric patients {hazard ratio 1.92 [95% confidence interval (CI) 1.25-2.95); 1.99 (1.26-3.15) and 1.98 (1.28-3.06) for proteinuria 0.15-0.49, 0.5-1 and >1 g/day, respectively}, whereas in non-diabetics the mortality risk increased only for proteinuria 0.5-1 g/day [HR 1.60 (95% CI 1.07-2.40)] and >1 g/day [HR 1.69 (95% CI1.20-2.55)]. In both groups, CV risk had a trend similar to that of mortality. ESRD risk increased progressively across strata >0.5 g/day independent of diabetic status. CONCLUSIONS: We provide evidence that patients with non-proteinuric DM-CKD are not exposed to higher cardiorenal risk. In contrast, in the presence of moderate proteinuria and diabetes per se is associated with a higher risk of mortality and CV events, whereas the entity of abnormal proteinuria modulates ESRD risk independent of diabetes.
引用
- Minutolo R, Gabbai FB, Provenzano M, et al. Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies. Nephrol Dial Transplant. 2018. PMID: 29509925. doi:10.1093/ndt/gfy032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。